Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares (KNSA) is a publicly traded Healthcare sector company. As of May 21, 2026, KNSA trades at $58.64 with a market cap of $4.13B and a P/E ratio of 54.96. KNSA moved +1.84% today. Year to date, KNSA is +32.20%; over the trailing twelve months it is +103.30%. Its 52-week range spans $17.82 to $59.87. Analyst consensus is strong buy with an average price target of $64.00. Rallies surfaces KNSA's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Hedge funds tracked by Rallies that own KNSA include Orbimed Advisors. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares.
| Metric | Value |
|---|---|
| Price | $58.64 |
| Market Cap | $4.13B |
| P/E Ratio | 54.96 |
| EPS | $0.98 |
| Dividend Yield | 0.00% |
| 52-Week High | $59.87 |
| 52-Week Low | $17.82 |
| Volume | 6 |
| Avg Volume | 0 |
| Revenue (TTM) | $754.04M |
| Net Income | $73.06M |
| Gross Margin | 89.31% |
7 analysts cover KNSA: 0 strong buy, 7 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $64.00.